SCHEMBL2293350

SCHEMBL2293350

CCc1cc(OC)cc(OCC(N)=O)c1-c1nc2ccc(F)cn2c1Nc1c(C)ccc(Cl)c1C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.35
TRPA1 O75762 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 2/20 0.35
GLA P06280 1/20 0.35
RAB9A P51151 1/20 0.35
MAPT P10636 6/20 0.34
GAA P10253 6/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
IGF1R P08069 1/20 0.32
TRIM33 Q9UPN9 2/20 0.32
TRIM24 O15164 1/20 0.32
PTGER2 P43116 1/20 0.31
TP53 P04637 2/20 0.31
THRB P10828 1/20 0.31
NR1H4 Q96RI1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289540 0.93 TRPA1 (0.36) CNR2TRPA1SMN1; SMN2LMNAGLA
SCHEMBL2295321 0.91 GAA (0.39) CNR2TRPA1SMN1; SMN2LMNAGLA
SCHEMBL2287599 0.90 GAA (0.41) TRPA1SMN1; SMN2MAPTGAAKDM4E
SCHEMBL2287002 0.90 TRPA1 (0.38) TRPA1SMN1; SMN2LMNAGLARAB9A
SCHEMBL2295061 0.89 MAPT (0.40) TRPA1SMN1; SMN2MAPTGAAKDM4E
SCHEMBL2290845 0.87 TRIM33 (0.38) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2290337 0.86 TRPA1 (0.41) TRPA1MAPTGAAALDH1A1CYP11B1
SCHEMBL2289541 0.86 TRPA1 (0.41) CNR2TRPA1SMN1; SMN2LMNAGLA
SCHEMBL2290931 0.86 MAPT (0.38) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2287227 0.86 GAA (0.42) TRPA1SMN1; SMN2MAPTGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 CNR2 589/4885TRPA1 1229/4885SMN1; SMN2 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.